D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia
| Autor: | Néstor J. Aparicio, Luis Schwarzstein, Andrew V. Schally |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Adult
Male Infertility endocrine system medicine.medical_specialty Time Factors Urology Endocrinology Diabetes and Metabolism Gonadotropin-Releasing Hormone Basal (phylogenetics) D tryptophan Internal medicine medicine Humans Triptorelin Pamoate Testosterone - serum Sperm Count Spermatid business.industry Oligospermia Luteinizing Hormone medicine.disease Prolactin Endocrinology medicine.anatomical_structure Reproductive Medicine Sperm Motility Follicle Stimulating Hormone Luteinizing hormone business Hormone |
| Zdroj: | International Journal of Andrology. 5:171-178 |
| ISSN: | 1365-2605 0105-6263 |
| DOI: | 10.1111/j.1365-2605.1982.tb00244.x |
| Popis: | D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days at a dose of 5 micrograms every 2 days, 10 micrograms daily or 10 micrograms every 2 days. There was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 micrograms daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment. D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text